Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

Richard Pebody*, Nicholas Andrews, D. M. Fleming, J. McMenamin, S. Cottrell, B. Smyth, H. Durnall, C. Robertson, W. Carman, Joanna Ellis, P. Sebastian-Pillai, Maria Zambon, C. Kearns, C. Moore, D. R.H. Thomas, John Watson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5-to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI-6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5-to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

Original languageEnglish
Pages (from-to)620-630
Number of pages11
JournalEpidemiology and Infection
Volume141
Issue number3
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Influenza
  • influenza vaccines
  • vaccine-preventable diseases

Fingerprint

Dive into the research topics of 'Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom'. Together they form a unique fingerprint.

Cite this